尼莫地平与氟桂利嗪治疗偏头痛的疗效及安全性对比

Comparison of Efficacy and Safety of Nimodipine and Flunarizine in the Treatment of Migraine

目的探讨尼莫地平与氟桂利嗪治疗偏头痛患者的疗效及不良反应。方法选择我院2017年7月—2018年1月收治的38例偏头痛患者作为尼莫地平组,选择同期收治的38例偏头痛患者作为氟桂利嗪组。比较两组临床疗效与不良反应发生情况。结果尼莫地平组有效率为89.47%,氟桂利嗪组有效率为92.11%,差异无统计学意义(P>0.05);尼莫地平组不良反应发生率为5.26%,氟桂利嗪不良反应发生率为23.68%,差异有统计学意义(P<0.05)。结论针对偏头痛患者,尼莫地平与氟桂利嗪的临床疗效相当,但尼莫地平引发的不良反应较少,选择尼莫地平治疗偏头痛的安全性更为理想。

Objective To investigate the efficacy and adverse reactions of nimodipine and flunarizine in the treatment of migraine.Methods A total of 38 patients with migraine who were admitted to our hospital from July 2017 to January 2018 were selected as nimodipine group.38 patients with migraine who were treated at the same time were selected as flunarizine group.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The effective rate was 89.47%in the nimodipine group and 92.11%in the flunarizine group.The difference was not statistically significant(P>0.05).The incidence of adverse reactions in the nimodipine group was 5.26%.The incidence of adverse reactions was 23.68%in flunarizine group,the difference with significant difference(P<0.05).Conclusion For migraine patients,the clinical efficacy of nimodipine and flunarizine is comparable,but the adverse reactions caused by nimodipine are less,and the safety of nimodipine in the treatment of migraine is more ideal.